Get the Stockscreener App
38.25
3.38%
1.25
Pre-market:
38.30
0.05
+0.13%
Harmony Biosciences Holdings Inc stock is traded at $38.25, with a volume of 543.62K.
It is up +3.38% in the last 24 hours and up +24.51% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$37.00
Open:
$36.985
24h Volume:
543.62K
Relative Volume:
0.58
Market Cap:
$2.20B
Revenue:
$772.53M
Net Income/Loss:
$180.90M
P/E Ratio:
12.33
EPS:
3.1024
Net Cash Flow:
$258.73M
1W Performance:
+7.56%
1M Performance:
+24.51%
6M Performance:
+8.79%
1Y Performance:
+9.54%
1-Day Range:
$36.86
$38.80
1-Week Range:
$35.14
$38.80
52-Week Range:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
38.25 | 2.13B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastPrice Momentum Alerts & Fast Growing Capital Gains - earlytimes.in
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MyChesCo
(HRMY) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Harmony Biosciences Holdings Inc. stock deliver surprise earnings beatEarnings Overview Summary & Verified Swing Trading Watchlist - BỘ NỘI VỤ
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results - Investing.com Canada
Harmony Biosciences stock reaffirmed at Outperform by Oppenheimer - Investing.com Canada
HC Wainwright & Co. Reiterates Harmony Biosciences Holdings (HRMY) Buy Recommendation - Nasdaq
Harmony Biosciences reports positive results for pitolisant GR formulation By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for HRMY, Maintains Price Ta - GuruFocus
Needham Reiterates Buy Rating on HRMY with Unchanged Price Targe - GuruFocus
Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results - marketscreener.com
Harmony Biosciences (HRMY) Advances with New Pitolisant Formulat - GuruFocus
Harmony Biosciences reports positive results for pitolisant GR formulation - Investing.com
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation - Lelezard
Harmony Biosciences reports positive pitolisant bioequivalence study results - StreetInsider
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet - StreetInsider
CFO Kapadia Files To Sell 3,427 Of Harmony Biosciences Holdings Inc [HRMY] - TradingView
Is Harmony Biosciences Holdings Inc. stock supported by strong cash flows2025 Technical Overview & Smart Investment Allocation Tips - newser.com
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb - simplywall.st
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - BioSpace
What insider trading reveals about Harmony Biosciences Holdings Inc. stockEarnings Growth Report & Low Risk Entry Point Guides - newser.com
Harmony Advances First Human Study of Orexin 2 Agonist - Sleep Review
Why Harmony Biosciences Holdings Inc. stock is favored by top institutionsInsider Buying & Safe Capital Investment Plans - newser.com
Why Harmony Biosciences Holdings Inc. stock could benefit from AI revolution - newser.com
Harmony Biosciences Initiates Patient Dosing in BP1.15205 Study for Central Disorders of Hypersomnolence - MarketScreener
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):